作者
S Harari, A Caminati, Carlo Albera, C Vancheri, V Poletti, A Pesci, F Luppi, C Saltini, Carlo Agostini, Elena Bargagli, A Sebastiani, A Sanduzzi, V Giunta, R Della Porta, GP Bandelli, S Puglisi, S Tomassetti, A Biffi, S Cerri, A Mari, F Cinetto, Francesca Tirelli, G Farinelli, Marialuisa Bocchino, Claudia Specchia, M Confalonieri
发表日期
2015/7/1
期刊
Respiratory Medicine
卷号
109
期号
7
页码范围
904-913
出版商
WB Saunders
简介
Background
In this retrospective Italian study, which involved all major national interstitial lung diseases centers, we evaluated the effect of pirfenidone on disease progression in patients with IPF.
Methods
We retrospectively studied 128 patients diagnosed with mild, moderate or severe IPF, and the decline in lung function monitored during the one-year treatment with pirfenidone was compared with the decline measured during the one-year pre-treatment period.
Results
At baseline (first pirfenidone prescription), the mean percentage forced vital capacity (FVC) was 75% (35–143%) of predicted, and the mean percentage diffuse lung capacity (DLCO) was 47% (17–120%) of predicted. Forty-eight patients (37.5%) had mild disease (GAP index stage I), 64 patients (50%) had moderate IPF (stage II), and 8 patients (6.3%) had severe disease (stage III).
In the whole population, pirfenidone attenuated the decline in FVC (p …
学术搜索中的文章
S Harari, A Caminati, C Albera, C Vancheri, V Poletti… - Respiratory Medicine, 2015
